Published in Vaccine Weekly, January 24th, 2007
With these developments, the company plans to pursue three pharmaceutical programs focused on the development of novel treatments for HIV, cancer and inflammatory diseases. The company changed its name to Ardea Biosciences, Inc. effective December 21, 2006 and expects that its common stock will be traded under the new name and a new ticker symbol (to be assigned by Nasdaq) in the near future.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly